AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies, particularly in the areas of maternal health, anaemia management, and other specialised treatments.
With a strong focus on delivering unique products, AMAG's portfolio includes well-regarded medications that address critical health needs, setting them apart in a competitive market. The company has achieved significant milestones, including strategic partnerships and product approvals that enhance its market position.
AMAG Pharmaceuticals continues to drive advancements in healthcare, committed to improving patient outcomes through its specialised pharmaceutical solutions.
-15 vs industry average
AMAG Pharmaceuticals, Inc.’s score of 23 is lower than 37% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at AMAG Pharmaceuticals, Inc.?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2025
Reported emissions
Scope 3 accounts for ••• of total emissions.
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
AMAG Pharmaceuticals, Inc., a pharmaceutical preparation manufacturer headquartered in the US, reported Scope 1 and 2 emissions of approximately 165,000 kg CO2e in 2022. This represents a slight decrease from approximately 168,000 kg CO2e reported in 2021. Currently, AMAG Pharmaceuticals, Inc.'s disclosed climate commitments do not include specific reduction targets or participation in initiatives like the Science Based Targets initiative (SBTi). The company's emissions data for 2021 and 2022 are for Scope 1 and 2 combined, with Scope 3 data, such as purchased goods and services, not yet disclosed. It's important to note that AMAG Pharmaceuticals, Inc.'s data is part of a cascaded reporting structure. The company is a current subsidiary, and the provided emissions data originates from AMAG Pharmaceuticals, Inc. itself at cascade level 0.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
AMAG Pharmaceuticals, Inc.’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for AMAG Pharmaceuticals, Inc. yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
AMAG Pharmaceuticals, Inc.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project